Clinical Trials Directory

Trials / Unknown

UnknownNCT03770520

Graft Patency of QFR-guided Versus Angio-guided Coronary Artery Bypass Grafting

The Clinical Effect of QFR-guided Coronary Artery Bypass Grafting: a Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
208 (estimated)
Sponsor
Beijing Anzhen Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Coronary artery bypass grafting(CABG) is the golden standard for severe coronary artery disease(CAD), the current surgery strategy is mainly based on coronary angiography(CAG), but many trials of PCI have shown that visually stenosis in CAG may not have functional significance. The aim of this study is to investigate if the Quantitative Flow Ratio (QFR) can be adopted in CABG and achieve a better graft patency.

Detailed description

CABG is the major treatment of three vessels or left main disease. CAG is the main basis on choosing the vessels to graft, however, some of the grafts occluded shortly after surgery due to competitive flow, these vessels may not be significantly stenosis in functional assessment such as Fractional Flow Reserve (FFR). Quantitative Flow Ratio (QFR) is a novel method for evaluating the functional significance of coronary stenosis. Comparing to FFR, there is no need for pressure wire or ATP when performing QFR. This study plan to investigate the clinical effect of QFR in CABG, all patients included will be allocated 1:1 into two groups: QFR-guided and Angio-guided, QFR-guided group will be performed a CABG based on the result of QFR, the other group will be based on heart team discussion of CAG, CTA will be adopted to evaluate the 1 year graft patency.

Conditions

Interventions

TypeNameDescription
PROCEDUREQFR-guided CABGCABG surgery based on CAG and QFR
PROCEDUREAngio-guided CABGCABG surgery based on heart team discussion of CAG

Timeline

Start date
2017-02-01
Primary completion
2020-01-01
Completion
2020-08-30
First posted
2018-12-10
Last updated
2018-12-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03770520. Inclusion in this directory is not an endorsement.